翰森制药(03692)：甲磺酸阿美替尼片单药治疗于欧盟获批上市

Core Viewpoint - Hansoh Pharmaceutical (03692) has received approval from the European Commission for its innovative drug, Amivantamab (Chinese trade name: 阿美乐®, overseas trade name: Aumseqa®), for the treatment of advanced non-small cell lung cancer (NSCLC) in adult patients [1] Group 1 - The drug is approved for use as a first-line treatment for adult patients with advanced NSCLC who have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations [1] - It is also approved for the treatment of adult patients with advanced EGFR T790M mutation-positive NSCLC [1] - The approval was based on a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) [1]